DeepMed Research

Rznomics Inc.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination with Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects with Hepatocellular Carcinoma

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma (HCC)

Interventions: Drug: RZ-001 Dose 1
Drug: RZ-001 Dose 2
Drug: RZ-001 Dose 3

First Posted Date: 2024-11-19

Last Posted Date: 2025-01-08

Lead Sponsor: Rznomics, Inc.

Target Recruit Count: 45

Registration Number: NCT06695026

Locations: 🇰🇷
Kyungpook National University Hospital, Deagu, Korea, Republic of
🇰🇷
Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 2 locations

Expanded Access Program for GBM Subjects

Conditions: Glioblastoma

First Posted Date: 2024-11-06

Last Posted Date: 2025-01-08

Lead Sponsor: Rznomics, Inc.

Registration Number: NCT06676891

Locations: 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Glioblastoma

Phase 1

Recruiting

Conditions: Glioblastoma

Interventions: Drug: RZ-001
Combination Product: VGCV

First Posted Date: 2023-10-26

Last Posted Date: 2024-11-06

Lead Sponsor: Rznomics, Inc.

Target Recruit Count: 43

Registration Number: NCT06102525

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

and more 1 locations

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma

Phase 1

Active, not recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: RZ-001 Dose 1
Drug: RZ-001 Dose 2
Drug: RZ-001 Dose 3
Drug: RZ-001 Dose 4

First Posted Date: 2022-10-27

Last Posted Date: 2024-11-04

Lead Sponsor: Rznomics, Inc.

Target Recruit Count: 42

Registration Number: NCT05595473

Locations: 🇰🇷
Kyungpook National University Hospital, Deagu, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Severance Hospital, Seoul, Korea, Republic of

and more 2 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy